Home » Stocks » Fate Therapeutics

Fate Therapeutics, Inc. (FATE)

Stock Price: $33.83 USD 0.41 (1.23%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $34.48 +0.65 (1.92%) Aug 7, 5:26 PM

Stock Price Chart

Key Info

Market Cap 2.94B
Revenue (ttm) 13.21M
Net Income (ttm) -116.50M
Shares Out 86.84M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $33.83
Previous Close $33.42
Change ($) 0.41
Change (%) 1.23%
Day's Open 33.57
Day's Range 33.20 - 34.65
Day's Volume 507,713
52-Week Range 12.59 - 38.52

More Stats

Market Cap 2.94B
Enterprise Value 2.47B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 86.84M
Float 72.93M
EPS (basic) -1.57
EPS (diluted) -1.57
FCF / Share -0.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12.38M
Short Ratio 12.38
Short % of Float 19.80%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 222.39
PB Ratio 12.97
Revenue 13.21M
Operating Income -119.40M
Net Income -116.50M
Free Cash Flow -38.77M
Net Cash 467.60M
Net Cash / Share 5.38
Gross Margin -583.53%
Operating Margin -903.76%
Profit Margin -881.90%
FCF Margin -293.43%
ROA -17.49%
ROE -38.73%
ROIC -57.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 14
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$38.94*
(15.10% upside)
Low
29.0
Current: $33.83
High
59.0
Target: 38.94
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue10.684.744.114.402.43-0.972.671.17
Revenue Growth125.32%15.44%-6.72%81.08%---63.63%128.21%-
Gross Profit10.684.744.114.402.43-0.972.671.17
Operating Income-101-67.09-42.13-31.96-27.78-24.90-17.68-13.56-13.29
Net Income-98.15-66.60-42.95-33.46-29.99-25.88-20.89-14.24-13.43
Shares Outstanding68.1956.2041.9831.7525.4820.455.901.090.83
Earnings Per Share-1.44-1.19-1.02-1.05-1.18-1.27-3.54-13.06-16.16
Operating Cash Flow-83.18-38.65-36.82-29.82-18.40-22.42-15.37-13.27-12.15
Capital Expenditures-7.40-2.30-1.73-0.44-1.50-0.88-0.24-0.710.20
Free Cash Flow-90.57-40.95-38.54-30.26-19.90-23.30-15.61-13.98-11.95
Cash & Equivalents22220110192.2364.9349.2254.169.216.51
Total Debt26.9314.8814.8110.6918.2419.611.733.674.84
Net Cash / Debt19518686.2681.5546.6929.6252.435.541.67
Assets30221310595.0567.9651.1855.5811.087.85
Liabilities57.5252.5628.1021.8929.9222.844.7463.9058.54
Book Value24516077.1973.1538.0428.3450.85-52.83-50.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fate Therapeutics, Inc.
Country United States
Employees 178
CEO J. Scott Wolchko

Stock Information

Ticker Symbol FATE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FATE
IPO Date October 1, 2013

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.